Question is do we buy now or wait for the hiccups which they will definitely encounter by taking on two large implementations at the same time which may provide a better buying opportunity.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%